NeoCore Technology Co., Ltd. (TPEX: 4131)
Health Care · Biotechnology · TW
NT$31.50
-2.17% today · -6.1% 1Y
NeoCore Technology Co., Ltd. (TPEX: 4131) operates in the Biotechnology industry within the Health Care sector. The company is valued at $39.43M and employs 44 people.
Over the last twelve months the share price has lost 6.1%, trading between 30.10 and 42.45.
Tweenvest scores NeoCore Technology Co., Ltd. across four factors: quality 39/100, value 70/100, growth 67/100. Its strongest factor is value.
4131 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $39.43M
- Revenue (TTM)
- $8.72M
- P/E
- —
- EPS
- -0.71
- Dividend yield
- —
- Beta (5Y)
- -0.27
- 52-week high
- NT$42.45
- 52-week low
- NT$30.10
- Avg volume (3M)
- —
- Shares outstanding
- 39.86M
- Employees
- 44
- Next earnings
- —
About NeoCore Technology Co., Ltd.
NeoCore Technology Co., Ltd. is primarily engaged in the creation, manufacture, and distribution of biochips and advanced rapid nucleic acid hybridization devices. Their extensive product range features systems designed for food safety screening, human diagnostic arrays, agricultural analysis, and specific food examination arrays, in addition to a variety of laboratory instruments and DNA kits. The company further provides a suite of services, encompassing laboratory planning, design, and additional specialized support. Beyond its core biotech operations, NeoCore also participates in the wholesale and retail market for contact lenses. The firm, which was established in 1987 and is based in Tainan, Taiwan, underwent a name change in July 2023, transitioning from its former identity as DR. Chip Biotechnology Incorporation to its current name.
- ISIN
- TW0004131008
- Founded
- 1987
- Listed since
- Dec 31, 2007
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.29 | +0.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.02 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $555.26 | +1.40% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $837.90 | +1.13% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.60 | +13.47% |
Figures last refreshed Aug 18, 2026.